Genexine (KOSDAQ: 095700), a Korean clinical-stage biopharmaceutical firm dedicated to developing innovative biologics for critical medical needs, has announced a merger with EPD Biotherapeutics (referred to as ‘EPD Bio’), a…
The ‘In Vitro Diagnostic Collaboration and Licensing Deals 2016-2024’ report offers an extensive analysis and unprecedented access to collaboration and licensing agreements in the global biopharma industry. Updated and meticulously…
Owkin, the first end-to-end AI-biotech unicorn specializing in AI-driven precision drug discovery, development, and diagnostics, has announced its expansion into the DACH region (Germany, Austria, and Switzerland). This follows partnerships…
During its annual event “BIG UP,” French Tech Saint-Etienne Lyon awarded the BIG Start-up of the Year trophy to a start-up that exemplifies the region’s innovation and richness. French Tech…
The Antibiotic Collaboration and Licensing Deals 2016-2024 report has been added to ResearchAndMarkets.com’s offerings. This report provides a comprehensive understanding and unprecedented access to antibiotic deals made by the world’s…
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that its Phase II/III SKYSCRAPER-06 study did not achieve its primary endpoints in evaluating tiragolumab in…
BenevolentAI (Euronext Amsterdam: BAI), a pioneering force in applying advanced artificial intelligence (AI) to expedite biopharma drug discovery, has announced changes to its Executive Leadership Team (ELT) following the recent…
Owkin, the pioneering AI-biotech unicorn specializing in AI-driven precision drug discovery, development, and diagnostics, has launched its expansion into the DACH region (Germany, Austria, and Switzerland). This expansion follows strategic…
During its annual event “BIG UP,” French Tech Saint-Etienne Lyon awarded the prestigious BIG Start-up of the Year trophy, recognizing a start-up that embodies innovation and vitality within the region.…
Exactly 120 years after the establishment of “Turn- und Spielverein der Farbenfabriken vorm. Friedr. Bayer & Co.”, the first Bayer sports club in Germany, Bill Anderson, CEO of Bayer AG,…
AstraZeneca’s Imfinzi (durvalumab) and Lynparza (olaparib) have been recommended for approval in the European Union (EU) for patients with primary advanced or recurrent endometrial cancer. The combination of Imfinzi plus…
AstraZeneca’s Marketing Authorisation Application (MAA) for sipavibart has been accepted under the accelerated assessment procedure by the European Medicines Agency (EMA) for the pre-exposure prophylaxis (prevention) of COVID-19 in immunocompromised…